<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924325</url>
  </required_header>
  <id_info>
    <org_study_id>Xijing-ADANCE</org_study_id>
    <nct_id>NCT01924325</nct_id>
  </id_info>
  <brief_title>Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events</brief_title>
  <acronym>ADANCE</acronym>
  <official_title>Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease
      with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin
      treatment reduced the risk of recurrent stroke and was not associated with increased
      hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is
      proved to be as effective as traditional anticoagulants with less risk of bleeding events.

      To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized,
      double-blind, multicenter, controlled clinical trial has been designed. The investigators
      will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and
      aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling
      cerebrovascular event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ADANCE study is a randomized, double-blind clinical trial with a target enrollment of
      3,000 Chinese patients. Two subtypes of patients will be enrolled: I, acute disabling
      ischemic stroke (&lt;24 hours of symptoms onset); II, acute TIA (&lt;24 hours of symptoms onset).

      Patients will be randomized into 3 groups:

      Ⅰ Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with
      placebo apixaban twice daily.

      Ⅱ Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin
      from day 1 to day 21.

      Ⅲ Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from
      day 1 to day 21.

      From day 22 to 3 months, all patients will receive 75-mg dose of clopidogrel long-term
      antiplatelet therapy.

      The primary efficacy end point is percentage of patients with new stroke (ischemic or
      hemorrhage) at 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with new stroke (ischemic or hemorrhage)</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NIHSS scores</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>moderate to severe bleeding events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events/severe adverse events reported by the investigators</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>TIA</condition>
  <arm_group>
    <arm_group_label>Dual-antiplatelet Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban 2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>orally active direct factor Xa inhibitor</description>
    <arm_group_label>Apixaban 2.5mg</arm_group_label>
    <arm_group_label>Apixaban 5mg</arm_group_label>
    <other_name>Eliquis</other_name>
    <other_name>BMS-562247</other_name>
    <other_name>BMS-562247-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor</description>
    <arm_group_label>Dual-antiplatelet Therapy</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Clopivid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>a non-steroidal anti-inflammatory drug</description>
    <arm_group_label>Dual-antiplatelet Therapy</arm_group_label>
    <other_name>Acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Dual-antiplatelet Therapy</arm_group_label>
    <arm_group_label>Apixaban 2.5mg</arm_group_label>
    <arm_group_label>Apixaban 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (male or female ≥18 years old)

          -  Acute nondisabling ischemic stroke (NIHSS ≤3 at the time of randomization) that can be
             treated with study drug within 24 hours of symptoms onset. Symptom onset is defined by
             the &quot;last see normal&quot; principle

          -  TIA (neurologic deficit attributed to focal brain ischemia, with resolution of the
             deficit within 24 hours of symptom onset), that can be treated with investigational
             medication within 24 hours of symptoms onset. Symptom onset is defined by the &quot;last
             see normal&quot; principle

          -  Informed consent signed

        Exclusion Criteria:

          -  Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor,
             abscess or other major nonischemic brain disease, on baseline head CT or MRI scan

          -  mRS score &gt;2 at randomization (premorbid historical assessment) NIHSS ≥4 at
             randomization

          -  Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves,
             deep venous thrombosis, pulmonary embolism or known hypercoagulable state)

          -  Contraindication to investigational medications

          -  Thrombolysis for ischemic stroke within preceding 7 days

          -  History of intracranial hemorrhage

          -  Current treatment (last dose given within 10 days before randomization) with heparin
             therapy or oral anticoagulation

          -  Gastrointestinal bleed or major surgery within 3 months

          -  Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          -  TIA or minor stroke induced by angiography or surgery

          -  Severe noncardiovascular comorbidity with life expectancy &lt;3 months

          -  Women of childbearing age not practicing reliable contraception who do not have a
             documented negative pregnancy test result

          -  Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;30 ml/min Severe
             hepatic insufficiency (Child-Pugh score B to C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department,Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuedong Liu, M.D.</last_name>
    <phone>+86 029 84775055</phone>
    <email>liuxued@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Yang, M.D. Ph.D.</last_name>
      <phone>+86 029 84773214</phone>
      <email>fyangx@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Gang Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apixaban</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>aspirin</keyword>
  <keyword>new oral anticoagulant</keyword>
  <keyword>TIA</keyword>
  <keyword>acute minor ischemic stroke</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

